You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.
The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.
Noridian is also developing a generic policy for donor-derived cfDNA tests that will include several commercially available tests, Natera said.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.
The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
The company reported $38.4 million in total revenues for the quarter and said testing services revenues rose 46 percent year over year.
The ALARM Partnership is being launched to measure the impact of AlloSure and RemoTraC on lung transplant patients.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
The company said the COVID-19 pandemic and resulting stay-at-home orders have led to a slowdown in testing service volumes in recent weeks.
The deal includes key testing services like Transplant's TruGraf blood test and Viracor's TRAC test, along with Viracor Eurofins' new SARS-CoV-2 test.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.